RGD Reference Report - Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker. - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker.

Authors: Behrouz Sharif, Shahin  Hashemzadeh, Shahriar  Mousavi Ardehaie, Reza  Eftekharsadat, Amirtaher  Ghojazadeh, Mortaza  Mehrtash, Amir Hossein  Estiar, Mehrdad Asghari  Teimoori-Toolabi, Ladan  Sakhinia, Ebrahim 
Citation: Behrouz Sharif S, etal., Oncol Lett. 2016 Dec;12(6):5335-5343. doi: 10.3892/ol.2016.5327. Epub 2016 Oct 31.
RGD ID: 150520010
Pubmed: PMID:28105243   (View Abstract at PubMed)
PMCID: PMC5228494   (View Article at PubMed Central)
DOI: DOI:10.3892/ol.2016.5327   (Journal Full-text)

Colorectal cancer (CRC) is one of the most common malignancies, and the third leading cause of cancer mortality worldwide. Timely detection of CRC in patients with earlier stages provides the highest rate of survival. Epigenetic alterations are important in the occurrence and progression of CRC, and represent the primary modifications of cancer cells. Therefore, detection of these alterations in CRC cases are thought to hold great promise as diagnostic biomarkers. It has been shown that the SEPT9 and NTRK3 genes are aberrantly methylated and their detection can be used as biomarkers for early diagnosis of CRC. The present study analyzed promoter methylation status of these genes in CRC patients. Genomic DNA was extracted from 45 CRC and paired adjacent healthy tissues and undergone bisulfite conversion, and the methylation status of NTRK3 and SEPT9 were defined using the MS-HRM assay. Our results showed that there are statistically significant differences in methylation status of NTRK3 and specially SEPT9 between CRC and adjacent normal tissues (P<0.001). High sensitivity and specificity for a specific location in SEPT9 gene promoter as a diagnostic biomarker was observed. SEPT9 promoter hypermethylation may serve as a promising biomarker for the detection of CRC development. However, to validate the biomarker potential of NTRK3 there is a requirement for further investigation.

RGD Manual Disease Annotations    Click to see Annotation Detail View

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
NTRK3Humancolorectal cancer  IDA DNA:hypermethylation:promoterRGD 
Ntrk3Ratcolorectal cancer  ISONTRK3 (Homo sapiens)DNA:hypermethylation:promoterRGD 
Ntrk3Mousecolorectal cancer  ISONTRK3 (Homo sapiens)DNA:hypermethylation:promoterRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ntrk3  (neurotrophic receptor tyrosine kinase 3)

Genes (Mus musculus)
Ntrk3  (neurotrophic tyrosine kinase, receptor, type 3)

Genes (Homo sapiens)
NTRK3  (neurotrophic receptor tyrosine kinase 3)

Additional Information